First Manhattan CO Myovant Sciences Ltd. Transaction History

First Manhattan CO

  • $31.9 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Nov 13, 2019
SELL
$5.19 - $9.46 $2.08 Million - $3.78 Million
-400,000 Closed
0 $0
Q2 2019

Aug 16, 2019
BUY
$8.69 - $25.0 $3.32 Million - $9.55 Million
382,195 Added 2146.56%
400,000 $3.62 Million
Q4 2018

Jan 30, 2019
BUY
$15.01 - $25.2 $267,253 - $448,686
17,805 New
17,805 $292,000

Others Institutions Holding MYOV

# of Institutions
6
Shares Held
61.3K
Call Options Held
0
Put Options Held
0
View Full List

About Myovant Sciences Ltd.

MYOV Quotes by TradingView
  • Ticker MYOV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 96,802,800
  • Description
  • Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...
More about MYOV
Track This Portfolio

Track First Manhattan CO Portfolio

Follow First Manhattan CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

News

Stay updated on First Manhattan CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email